Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

China · Delayed Price · Currency is CNY

44.42

-0.78 (-1.73%)

Jun 18, 2026, 3:00 PM CST

-32.68% (1Y)

Market Cap	3.50B -30.3%
Revenue (ttm)	892.24M +2.0%
Net Income	178.37M -44.1%
EPS	2.24 -44.4%
Shares Out	77.38M
PE Ratio	20.15
Forward PE	n/a
Dividend	2.00 (4.42%)
Ex-Dividend Date	Jun 1, 2026

Volume	457,282
Open	45.00
Previous Close	45.20
Day's Range	44.30 - 45.58
52-Week Range	44.30 - 78.20
Beta	0.18
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2009

Employees 992

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688606

Full Company Profile

Financial Performance

In 2025, Hangzhou Alltest Biotech's revenue was 905.34 million, an increase of 4.47% compared to the previous year's 866.58 million. Earnings were 220.19 million, a decrease of -27.20%.

Financial Statements